戒烟干预:全科视角的循证实践解读
美国约五分之一成人使用烟草制品,吸烟是可预防疾病和死亡的首位原因。每年近半数吸烟者尝试戒烟,但无支持戒烟者中仅至多二十分之一能维持至少六个月戒断。所有患者包括学龄儿童和青少年均应被询问吸烟情况,并提供循证戒烟治疗。
要点
- 采用5A框架(询问、建议、评估、协助、安排)可促进戒烟。
- 药物联合有效行为策略显著优于任一单独方案。
- 控烟药物延长使用(超过12周)较标准使用(6至12周)有更高持续戒烟率和更低复吸率。
核心结论
- 所有患者包括学龄儿童和青少年均应被询问吸烟情况并提供循证戒烟治疗。
- 药物联合有效行为策略显著优于任一单独方案。
- 控烟药物延长使用(超过12周)较标准使用(6至12周)有更高持续戒烟率和更低复吸率。
研究设计与样本
- 本文为综述,汇总戒烟干预相关临床研究证据与推荐。
主要发现
- 美国五分之一成人使用烟草制品,吸烟是可预防疾病和死亡首位原因。
- 每年近半数吸烟者尝试戒烟,无支持戒烟者中至多二十分之一维持至少六个月戒断。
- 5A框架(询问、建议、评估、协助、安排)可帮助临床医生促进戒烟。
- 药物联合有效行为策略显著优于任一单独方案。
- 控烟药物延长使用(超过12周)较标准使用(6至12周)有更高持续戒烟率和更低复吸率。
关键数值与推荐
- 美国FDA批准的戒烟药物包括尼古丁替代疗法、安非他酮和伐尼克兰。
- 电子烟未获美国FDA批准用于戒烟,支持其获益的证据不确凿。
- 推荐50至80岁、有20包年吸烟史且目前吸烟或过去15年内戒烟者进行肺癌筛查。
- 肺癌筛查应与戒烟工具和治疗相结合。
临床怎么用
- 全科医生应采用5A框架常规询问所有患者(含学龄儿童和青少年)吸烟情况并提供循证戒烟治疗。
- 优先联合药物与有效行为策略,并考虑控烟药物延长使用(超过12周)以提高持续戒烟率。
- 对符合条件者(50至80岁、20包年吸烟史、目前吸烟或过去15年内戒烟)将肺癌筛查与戒烟干预结合。
局限性
- 本文为综述,未报告原始研究的具体样本量、置信区间和P值等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the United States, 1 in 5 adults uses tobacco products. Cigarette smoking is the leading cause of preventable disease and death in the United States despite its known health effects. Although nearly one-half of people who smoke try to quit each year, only up to 1 in 20 who quit without support achieve abstinence for at least six months. All patients, including school-aged children and adolescents, should be asked if they smoke and offered evidence-based treatments for smoking cessation. Use of the 5 A's framework (ask, advise, assess, assist, arrange) can help clinicians promote smoking cessation. Clinical studies have demonstrated that combining pharmacotherapy with effective behavior strategies is significantly more effective than either approach alone. Pharmacotherapies approved by the U.S. Food and Drug Administration for smoking cessation include nicotine replacement therapy, bupropion, and varenicline. Extended use (greater than 12 weeks) of a controller therapy (varenicline, bupropion, or nicotine patch) is associated with significantly higher sustained quit rates and lower relapse rates than standard use (six to 12 weeks). e-Cigarettes are not approved by the U.S. Food and Drug Administration for smoking cessation, and evidence supporting their benefit is inconclusive. Lung cancer screening is recommended for adults 50 to 80 years of age who have a 20-pack-year smoking history and currently smoke or have quit within the past 15 years. Lung cancer screening should be combined with smoking cessation tools and treatment.
引用
- Gaddey HL, Dakkak M, Jackson NM, et al. Smoking Cessation Interventions. Am Fam Physician. 2022. PMID: 36379496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。